Int J Family Med Prim Care | Volume 2, Issue 1 | Case Study | Open Access

Venlafaxine Rechallenge - Associated with Neuroleptic Malignant Syndrome

Fareena Yasir

East Kent Hospitals University NHS Foundation Trust, UK

*Correspondance to: Fareena Yasir 

Fulltext PDF


Neuroleptic Malignant Syndrome (NMS) is an infrequent but a potentially life-threatening emergency, associated with the use of neuroleptic and antipsychotic medications. It is characterized by tetrad of symptoms including fever, rigidity, altered mental status and autonomic dysfunction. Although NMS is most commonly seen as a reaction to neuroleptics, its development has also been seen with use of non-neuroleptics agents that blocks central dopamine pathway. NMS was first described in 1960 with the use of Haloperidol. It has been associated with virtually all neuroleptics including newer atypical antipsychotics. The incidence rate ranges from 0.02% to 3%. However, the incidence rate as decreased with newer neuroleptics to 0.01% to 0.02%. Due to its lifethreatening nature, NMS requires prompt diagnosis and treatment, ruling out similar conditions such as Serotonin Syndrome and Malignant Hyperthermia.


Neuroleptic Malignant Syndrome (NMS); Parkinson disease; Hyperthermia; ED; CK; COVID


Yasir F. Venlafaxine Rechallenge - Associated with Neuroleptic Malignant Syndrome. Int J Fam Med Prim Care. 2021; 2(1):1029.

Subscribe to Our Newsletter